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Abstract
Viscerotropic disease (VD), a disease with high mortality, results from the dissemination of the yellow fever vaccine 
virus throughout the body. Twenty-six cases of VD following vaccination with the Bio-Manguinhos 17DD vaccine 
were reported, 21 from Brazil and 5 from other countries, of which 19 were confirmed, 4 probable and 3 suspect. 
These cases were not related to immunodeficiency diseases, but could be related to the existence of autoimmune 
diseases, such as systemic lupus erythematosus. Adverse neurological events following yellow fever vaccination are 
in general aseptic meningitis, with a good outcome, encephalitis, and autoimmune neurological events such as 
Guillain-Barré syndrome. In Rio Grande do Sul (2009) 2 cases of confirmed meningoencephalitis in newborns after 
yellow fever vaccination of a breastfeeding mother created a new and difficult problem to solve in a satisfactory 
manner. Bio-Manguinhos/Fiocruz is doing several studies to try to improve the yellow fever vaccine, such as a dose-
response study, with the objective to know if the vaccine can be administered in a smaller dose than usual, which 
perhaps would be safer, Also, further purification of the current vaccine, and studies for the development of a non-
live yellow fever vaccine are under way. 
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1. Introduction 
Yellow fever (YF) is in expansion in Brazil, with an eastward trend, menacing the highly populated coastal area. 
People from endemic areas or travelers to these areas are vaccinated. The yellow fever vaccine (YFV), a live 
attenuated virus strain (17DD) has been extensively studied, through molecular characterization, animal studies and 
clinical studies [1, 2, 3], and has shown genetic stability through repeated passages [4].The incidence of common 
adverse events, such as pain, myalgia and fever is at a low 4% of vaccinated people [5]. In the last 10 years, 
however, serious and even fatal adverse events have been reported after YFV administration. These are YFV-
associated viscerotropic disease (VD), due to dissemination of the vaccine virus to viscera, YFV-associated 
neurological disease (ND), which includes benign aseptic meningitis, encephalitis, and autoimmune central or 
peripheral disease (Guillain-Barré Syndrome, GBS), as well as hypersensitivity events or anaphylactic shock. 
The most serious adverse event is VD, which is characterized by a very high lethality. In Brazil, VD has been 
detected mostly after large vaccination campaigns in 1999-2001 and again in 2008-2009. Molecular studies of the 
virus isolated from these cases failed to find any significant mutation or contamination problems [6, 7]. 
Herein we present a summary of some post-marketing surveillance findings regarding serious adverse events after 
YF vaccination. 
1. Methods 
Since 1998, the National Immunizations Program at the Ministry of Health (MoH) established a National System for 
Surveillance of Adverse Events Following Immunization (AEFI), a manual on AEFI was conceived and adopted, 
which is now in its second edition, and an electronic database was implemented. The source of information is the 
30,000 Health Centers all over the country, with evaluation of events at state level and final classification at national 
level. There are electronic adverse events databases at state and federal levels, and the information is shared with the 
Bio-Manguinhos Pharmacovigilance Unit. The Customer Service and Marketing Division in Bio-Manguinhos / 
Fiocruz also receives complaints from customers, and a Pharmacovigilance Unit has been established, connected to 
the MoH and the Brazilian Regulatory  Authority (Anvisa). 
A manual on AEFI for intermediate level health professionals has also been written and distributed, so, by now, 
there is a general understanding in the country that, although vaccines are the best health intervention, they are not 
perfect, and their use must follow a risk-benefit analysis. Recently, we have used the World Health Organization 
Manual for Detection of Serious Adverse Events after YFV. Cases were classified according to the Centers for 
Disease Control and Prevention (CDC) criteria, with minor adaptations. Detection and diagnosis was done at local 
level, with consolidation of diagnosis at the state level and final diagnosis at central level, with the participation of 
experts. A network of state laboratories and reference laboratories at national level provide good support for 
differential diagnosis and confirmation of VD or ND, with capability to carry yellow fever virus isolation in cell 
cultures, RT-PCR, immunohistochemistry, histopathology, and specific serology. 
A Guideline for Investigation of Serious Adverse Events has also been developed and distributed, as well as a 
simple flow chart, explaining how to collect, transport and deliver samples from patients to laboratories. A special 
box for the collection of samples is sent to hospitals at the time of yellow fever vaccination campaigns. This is a 
one-contact sample procedure, useful for field work in difficult conditions.    
Another important source of information is sentinel hospitals in charge of the  detection of icterohemorrhagic febrile 
syndrome. This is a compulsory and immediate reporting. Differential diagnosis in Brazil includes wild yellow 
fever, VD, dengue, hantavirus, leptospirosis, meningococcal infection, malaria (Plasmodium falciparum), rickettsial 
infections, typhoid fever, Brazilian purpura fever and other arbovirus infections. 
International organizations also provided information on cases outside Brazil. 
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Adverse events cases are classified as confirmed, probable, suspect, discarded or inconclusive, according to 
CDC/WHO criteria. The Brazilian Ministry of Health has information on the number of YFV doses administered by 
age so that it is possible to precisely estimate the rates of adverse events in diverse age categories 
2. Results 
According to the Ministry of Health database, 1994 adverse events were reported between the years 2000 and 2008, 
when 101 564 083 YFV doses were administered. Serious adverse events were much more frequent after first dose 
immunization than after revaccination. Hypersensitivity events were detected at a frequency of 0.9/100 000 doses, of 
which anaphylactic shock represented 0.023/100 000 doses. YFV-associated ND was detected at a frequency of 
0.084/100 000 doses, and 26 VD cases were reported, 21 from Brazil and 5 from other countries, of which 19 were 
confirmed, 4 probable and 3 suspect cases. Of these, 10 were male, 15 female and 1 unknown (a 1975 case). Case 
fatality rate of VD was 92.3% (24/26 cases). 
Figure 1. YFV doses and YF-associated VD cases in Brazil, 1999-2009  
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Table 1. Incidence of VD cases (confirmed, probable and suspect) by age range, Brazil, 1999-2009 
Age range 
(years)
YFV doses administered VD cases Rate/100 000 doses 
administered
<1 13,795,220 0 0.000
1 5,028,332 0 0.000
2 2,137,966 0 0.000
3 1,894,257 1 0.053
4 2,035,814 2 0.098
5 a 9 5,660,823 1 0.018
10 a 14 11,580,677 2 0.017
15 a 59 59,134,044 11 0.019
60+ 6,382,260 3 0.047
Total 107,649,393 20 0.019
Since 1999, almost 108 million YFV doses have been administered in Brazil. During this period, VD cases have 
been reported chiefly during the large vaccination campaigns in 1999-2001 and again in 2008-2009 (Figure 1).
There was no clear-cut difference on incidence of VD cases by age groups (Table 1). In the 2009 YFV campaign, 
São Paulo state reported 3 confirmed and 2 probable cases of VD for 1 600 000 doses administered, amounting to a 
frequency of  0.31/100 000 doses.  
Rio Grande do Sul state, at about the same time, reported 2 confirmed and 2 probable VD cases for 3 600 000 doses 
administered (0.11/100 000 doses), 35 confirmed cases of aseptic meningitis (0.97/100 000 doses); and 2 probable 
GBS cases (0.06/100 000 doses). The total incidence of neurological cases was therefore about 1.1/100 000 doses. 
Almost all neurological cases recovered completely and without sequellae. These estimates suggest a higher rate of 
serious adverse events than was detected on the Ministry of Health database, which includes data from all over 
Brazil. Also, Rio Grande do Sul reported a case of demyelinating disease with confirmed optic neuritis, and two 
cases of encephalitis acquired through breast milk. 
3. Discussion 
Brazil has an established system for reporting adverse events after immunization. This system is not homogeneous, 
and has different sensitivities across the country. There is also a good capability for investigation of serious adverse 
events through a network of state laboratories and reference laboratories at national level. Cases are discussed at 
national level for final classification. 
The frequency of serious adverse events following vaccination with YFV has been increasing in the last 10 years in 
the country. Confirmed cases have been published, and recently confirmed cases will be published soon [8-14]. This 
is creating a serious dilemma, because the area of circulation of yellow fever is spreading in the country and in 
neighbor countries 
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There was no VD case reported in association with an immunodeficiency condition. There are indications that some 
immunological disturbances, not true immunodeficiencies, or genetic factors, might have plaid a role as factors for 
VD. Thymoma and thymectomy were reported as a risk factor [15], as these conditions are associated with 
autoimmunity [16]. In our case, three VD cases occurred in patients with SLE, and 2 others in sisters who had an 
aunt with SLE. We recently reported a suspect case of VD in a patient with SLE, who recovered [17]. 
Two brothers with Addison’s disease, 34 and 30 years of age, who were receiving physiological doses of 
corticosteroids died after administration of YFV. Although they were classified as probable cases, the evidence is in 
favor of a causal association with the vaccine. 
Neurological adverse events following vaccination with YFV are aseptic meningitis, which is of good prognosis, 
encephalitis, and autoimmune neurological events such as Guillain-Barré syndrome. The studies conducted in Rio 
Grande do Sul (2009) have shown that these are much more frequent than previously thought. Two cases of 
confirmed vaccine encephalitis in newborns after a breastfeeding mother vaccination created a new and difficult 
problem to solve in a satisfactory manner. 
The decision to vaccinate people against YF is taken considering the risk of disease and the risk of serious adverse 
events [18]. There are no clear risk factors that could contraindicate vaccination, besides those already in practice, 
such as contraindication to vaccinate infants below 6 months of age and immunodeficient people. The Brazilian data 
does not show evidence of increasing risk in older people, as was reported elsewhere [19, 20]. Transmission of 
encephalitis by transmission of vaccine virus through breast milk [21] increased the complexity of the decisions. A 
recent (January 2010) confirmed case of viscerotropic disease in a 10- month-old infant in Rio Grande do Sul 
discarded the idea that children in the first year of life could be protected from VD. 
Bio-Manguinhos/Fiocruz is conducting studies for a better understanding of the immunological response to yellow 
fever vaccine in individuals who received YFV with and without severe adverse events [17, 22-24]. Bio-
Manguinhos/Fiocruz is also doing several studies trying to improve the YFV, including a dose-response study, with 
the objective to know if it can be given in a smaller dose than it is usually given, which perhaps could be safer. 
Other studies include further vaccine purification, and studies for the development of a non-live vaccine. 
But, even as it stands now, YFV is a good vaccine and the most effective tool for the control of yellow fever, an 
extremely serious disease with a very high case fatality rate. Thanks to national vaccination, the incidence of yellow 
fever in Brazil has remained very low, in spite of the wide dissemination of the virus throughout the major part of 
the country. 
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